Eisai (ESAIY) and Biogen (BIIB) announced that humanized anti-soluble aggregated amyloid-beta monoclonal antibody “LEQEMBI” has been approved for once every four weeks intravenous maintenance dosing by the National Medical Products Administration, NMPA, in China.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIIB:
- Freeport-McMoRan, Biogen, Intel, Uranium Energy, CME Trending by Analysts
- Oracle initiated, Ulta Beauty upgraded: Wall Street’s top analyst calls
- Biogen initiated with a Buy at Jefferies
- Biogen’s Growth Potential Driven by Leqembi Sales and Diversified Pipeline
- Biogen, Eisai announces TGA of Australia approved LEQEMBI